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OBJECTIVES: While topical corticosteroids are first-line therapy for eosinophilic esophagitis (EoE), the data regarding long-term
effectiveness are lacking. We aimed to determine long-term histologic and endoscopic outcomes of maintenance therapy in EoE
steroid responders.
METHODS: We performed a retrospective study of adults with EoE at UNC Hospitals who had initial histologic response (o15 eos/
hpf) after 8 weeks of topical steroids, and maintained on therapy. Endoscopic and the histologic data were recorded at baseline
and follow-up endoscopies. Multivariable logistic regression was performed to assess loss of treatment response by steroid dose
at recurrence, and Kaplan–Meier analysis to calculate durability of disease remission.
RESULTS: Of 55 EoE patients with initial response to swallowed/topical fluticasone or budesonide over a median 11.7 months, 33
had at least two follow-up EGDs. Of these patients, 61% had histologic loss of response and worse endoscopic findings. There was
no difference in baseline steroid dose (P= 0.55) between the groups, but those maintained on their initial dose had lower odds
(OR: 0.10; 95% CI: 0.01, 0.90) of loss of response compared to those who had subsequent dose reduction. On survival analysis,
50% had loss of response to steroids by 18.5 months and 75% by 29.6 months.
CONCLUSIONS: In adult EoE steroid responders, loss of treatment response is common, and is associated with a steroid dose
reduction. Routinely lowering doses for maintenance steroids may provide inferior outcomes.
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INTRODUCTION
Eosinophilic esophagitis (EoE) is a chronic immune-mediated
condition characterized by eosinophilic infiltration of the
esophageal mucosa, leading to symptoms of esophageal
dysfunction.1,2 Current guidelines3 recommend that the first-
line pharmacologic treatment for EoE should be swallowed, or
topical, corticosteroids such as budesonide or fluticasone.
While there are some patients with a severe fibrostenotic
phenotype who may not respond very well to these
medications,4,5 most studies show initial histologic response
rates ranging from 50% to 490%.6–14 The preliminary data
have also shown that controlling inflammation with topical
corticosteroids can decrease the need for future dilations.15,16
As a result, topical corticosteroids are now commonly used for
the management of EoE for both inflammatory and fibroste-
notic phenotypes.
After an initial treatment course, there is controversy about
whether all patients with EoE need to be maintained
indefinitely on topical steroids for disease control.3,17 This is
because existing studies on the long-term outcomes of cortic-
osteroid treatment in adult EoE patients are limited.5,9,18,19
While these data consistently show nearly universal recurrent
disease after discontinuation of initial treatment,5,20 the long-
term efficacy, durability, and safety of maintenance steroid
treatment is not well understood. In addition, factors such as
treatment duration after initial response as well as the ideal
maintenance dose of steroids are not currently elucidated.
The aims of this study were to determine long-term
histologic and endoscopic outcomes, and durability of
response of maintenance topical corticosteroid treatment in
EoE patients who achieved an initial histologic response after
an 8-week course of topical corticosteroids. In addition, we
aimed to explore the impact of topical steroid dose and type on
the durability of ongoing histologic response.
METHODS
Study design and data source. We conducted a retro-
spective cohort study of EoE patients at the University of
North Carolina (UNC) Hospitals from 2006–2015 using the
UNC EoE Clinicopathologic database. The database
contains EoE patients of all ages who met consensus
guidelines1–3 for a new diagnosis of EoE, including symptoms
of esophageal dysfunction, ≥15 eosinophils per high-power
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field (eos/hpf) (hpf area= 0.24 mm2), non-response to a
high-dose proton-pump inhibitor trial, and exclusion of
competing causes. The details of this database have been
described previously.4,21–23
Study population, procedures, treatments, and
follow-up. All patients underwent a baseline endoscopy
where EoE was diagnosed. For this procedure, endoscopic
findings were noted and esophageal biopsies were obtained.
The peak eosinophil counts (eos/hpf) were determined from
esophageal biopsies as per clinical protocol. Patients with
PPI responsive esophageal eosinophilia (PPI-REE) were
excluded, so the cases are a PPI-non-responsive EoE group.
Following this, per clinical protocol at our institution, patients
were placed on either budesonide (0.5–1 mg twice daily,
based on patient age, with the aqueous formula mixed into a
slurry with 5 g of sucralose)8,24 or fluticasone (440–880 mcg
twice daily, based on patient age).6 After an 8-week course of
topical corticosteroid treatment, patients underwent a repeat
upper endoscopy with documentation of endoscopic and
histologic findings. Histologic responders were defined as
patients witho15 eos/hpf and non-responders as those with
≥15 eos/hpf.25 The prior published data from our cohort
showed initial histologic response in 57% of incident EoE
cases who received topical corticosteroids.26 After this initial
treatment course, patients continued to be treated on a
clinical basis, and topical steroid dose, type, and dose
adjustments were at the discretion and instruction of the
individual provider.
For this study, we only included adults ≥18 years of age
meeting EoE consensus guidelines who had an initial
histologic response (o15 eos/hpf) after an 8-week course of
topical corticosteroids (fluticasone or budesonide), and who
were subsequently maintained on steroid therapy for ≥75% of
the follow-up time.We determined this level of maintenance by
reviewing the electronic medical record for prescriptions
provided as well as clinic or endoscopy follow-up, which
included routine documentation of ongoing use and compli-
ance with the medication. Follow-up time was defined as time
from baseline endoscopy to the time of histologic loss of
response (defined as ≥ 15 eos/hpf) or to the end of the data
collection period. Endoscopic and the histologic data from any
upper endoscopy performed during the follow-up period were
collected. The endoscopic data included the presence of
edema, rings, exudates, furrows, or strictures. Since some
included the data pre-dating the EREFS scoring system,27 a
simplified endoscopic severity score (ESS) was used with
each EREFS finding (edema, rings, exudates, furrows, and
strictures) scored as absent or present (score range: 0–5).
The presence of candida and whether dilation was performed
at that endoscopy was also obtained. The histologic data
comprised of maximum eosinophil counts (eos/hpf).
At each endoscopy, the use and dose of proton-pump
inhibitors (PPI) or topical corticosteroids were noted. PPI dose
was categorized as high (twice a day), low (daily), or none. For
corticosteroids, the type (budesonide or fluticasone) and total
daily dose at each follow-up endoscopy were documented.
Detailed chart review was performed to determine the exact
start and stop dates for each course of corticosteroid
treatment. Any change in steroid dosing during the follow-up
period was directed by the clinical provider. Participants who
were enrolled in clinical trials for topical corticosteroids or
other alternate EoE therapies were excluded, aswere patients
undergoing dietary elimination therapy.
Statistical analysis. The data were analyzed at both the
patient and endoscopy level. For the per-patient analysis, only
the data up to the first episode of loss of steroid response or to
the end of the follow-up period in those with sustained steroid
response were included. Descriptive statistics were used to
summarize baseline patient characteristics. Bivariate analyses
were performed to determine the relationship between each
independent variable and steroid response, using Student’s
t-test and Wilcoxon rank-sum for continuous variables and
Pearson’s Χ2 tests for categorical variables. Multivariable
logistic regression was performed to calculate odds of loss
of response to steroid treatment based on steroid dose at the
time of recurrence, adjusted for steroid type, history of dilation,
and follow-up time. For this analysis, steroid dose was
dichotomized into a high (daily 41000 mcg of budesonide or
4880 mcg of fluticasone) or low (daily ≤1000 budesonide or
≤880 mcg of fluticasone) dose category.
For the per-endoscopy analysis, follow-up upper endosco-
pies were categorized into time periods from baseline
endoscopy: ≤3, 3–12, 12–24, 424 months, in order to
compare results to the previously reported data.18,19 For each
time period, we determined the mean ESS, maximum
eosinophil count, mean steroid dose, and proportion of
patients using a PPI. Kaplan–Meier analysis was used to
calculate the durability of topical corticosteroids in maintaining
histologic remission.
For the Kaplan–Meier survival analysis, repeated measures
for each patient were allowed and patients were not censored
at the time of first loss of response, as in the per-patient
analysis. Therefore, the entire time under observation for each
patient was incorporated and some patients may have had
recurrent loss of treatment response. All analyses were
performed using Stata 13 (College Station, TX, USA). The
study was approved by the University of North Carolina
Institutional Review Board.
RESULTS
Patient characteristics. There were 55 patients who met
the inclusion criteria (Table 1). Mean age was 39.9±11.9
years, 67% were men, and 96% were white. Most common
presenting symptoms were dysphagia (93%), food impaction
(49%), and heartburn (42%). Most common baseline endo-
scopic findings were esophageal rings (84%), furrows (73%),
and plaques (44%). Mean baseline eosinophil count was
69.7±71.1 eos/hpf. More than half of the sample had a
history of dilation, 75% were treated with budesonide, and
25% with fluticasone. The median follow-up time was
11.7 months.
Results from per-patient analysis. Out of the 55 patients,
33 had at least two subsequent endoscopies after the
baseline exam and were included in the per-patient analysis
(Table 2). The two subsequent endoscopies consisted of one
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showing initial response post-treatment and one assessing
the effect of maintenance therapy). Out of the 33 patients,
61% (n= 20) had histologic loss of response to treatment and
39% (n=13) maintained histologic response. There were no
differences in gender, race, symptom duration, or follow-up
time between those with loss of response and ongoing
response to topical corticosteroid therapy. Similarly, there
was no difference between the groups in endoscopic severity
score (ESS) and number of eosinophils at baseline or after
8 weeks of topical corticosteroid therapy. As expected, the
group with loss of response had a higher ESS score and
higher peak eosinophil count compared to the group with
ongoing response. Indications for follow-up EGD after initial
response during the maintenance period included surveil-
lance EGD to assess for ongoing maintenance steroid
response (n=21; 64%) or for recurrent symptoms such as
dysphagia (n=9; 27%), heartburn (n=2; 6%), or abdominal
pain (n=1; 3%).
While both groups were treated with comparable steroid
doses at baseline (P=0.55), those who had loss of treatment
responsewere ona significantly lower dose of budesonide at the
time of disease recurrence compared to those with ongoing
response (708 vs 1429 mcg, P=0.02). While the dose of
fluticasone was also lower in those with histologic recurrence,
this was not statistically significant (440 vs 733 mcg, P=0.57).
The significant difference in steroid dose at the time of
recurrence or end of follow-up period for ongoing responders
persisted onmultivariable logistic regression adjusted for steroid
type, history of dilation, and follow-up time. After initial histologic
response to topical corticosteroid therapy, those patients who
were maintained on a higher dose (daily 41000 mcg of
budesonide or 4880 mcg of fluticasone) had lower odds of
loss of treatment response (OR: 0.10; 95% CI: 0.01, 0.90)
compared to the patientswhose initial steroid dosewas reduced
(daily ≤1000 budesonide or ≤880 mcg of fluticasone).
Results from per-endoscopy analysis. There were a total
of 184 endoscopic exams that were included (Table 3). Peak
eosinophil counts and ESS scores were lowest within the first
6 months and increased subsequently during the follow-up
period (Figure 1). When the ESS and eosinophil count at
each follow-up time point was assessed in relation to topical
corticosteroid dose, there was an increase in ESS and peak
eos/hpf after 6 months from baseline exam that correlated
with decrease in budesonide dose (Figure 2). Notably, the
response did not improve with subsequent increase of
budesonide dose. For those on fluticasone, a similar trend
of loss of response was seen, but after 12 months compared
to 6 months with budesonide, and the increase in ESS and
Table 1 Sample characteristics
Steroid responders
(n=55)
Age, y, mean± s.d. 39.9±11.9
Male, n (%) 37 (67)
White, n (%) 52 (96)
Symptoms (n, %)
Dysphagia 51 (93)
Food impaction 27 (49)
Chest pain 11 (20)
Heartburn 23 (42)
Abdominal pain 6 (11)
Nausea 2 (4)
Vomiting 10 (18)
Failure to thrive 1 (2)
Symptom duration before diagnosis, y,
mean± s.d.
10.5±9.1
Atopic disease (n, %) 27 (49)
Allergic Rhinosinusitis (n, %) 35 (66)
Asthma (n, %) 11 (20)
Food allergy (n, %) 18 (35)
Baseline endoscopic findings (n, %)
Rings 46 (84)
Linear furrows 40 (73)
White plaques 24 (44)
Decreased vascularity 14 (25)
Crêpe-paper mucosa 0 (0)
Strictures 18 (33)
History of dilation (n, %) 31 (56)
Baseline eosinophil count, eos/hpf,
mean± s.d.
69.7±71.1
Steroid type, n (%)
Budesonide 41 (75)
Fluticasone 14 (25)
Follow-up time, months, median (IQR) 11.7 (3.7–24.2)
Table 2 Characteristics of participants with ongoing response and loss of
response following successful histologic response to steroid therapy
Loss of
responsea
(n=20)
Ongoing
response
(n=13)
P-value
Age, y, mean± s.d. 37.75±10.15 40.41±9.33 0.45
Male, n (%) 12 (60) 8 (62) 0.93
White, n (%) 19 (95) 13 (100) 0.41
Symptom duration
before diagnosis, y,
median (IQR)
8 (2–20) 10.5 (4.5–17.5) 0.54
Endoscopic Severity Score (ESS), median (IQR)
Baseline 4 (2–5) 3 (2–3) 0.07
Post-steroid 1 (1–1.5) 2 (1–2) 0.15
At recurrence or
end of follow-up
3 (1.5–4) 1 (1–2) 0.02
Eosinophil count, eos/hpf, median (IQR)
Baseline 47 (28–88) 50 (25–60) 0.59
Post-steroid 0 (0–3) 0 (0–2) 0.90
At recurrence or
end of follow-up
63 (28–95) 1 (1–5) o0.01
Steroid type, n (%) 0.02
Budesonide 18 (90) 7 (54)
Fluticasone 2 (10) 6 (46)
Daily steroid dose, mg, mean± s.d. (initial)
Budesonide 2018±1070 2286±756 0.55
Fluticasone 1760±0 1760±0 n/a
Daily steroid dose, mg, mean± s.d. (at recurrence or end of follow-up)
Budesonide 708±643 1429±732 0.02
Fluticasone 440±622 733±585 0.57
Follow-up time,
months, median
(IQR)
27 (15–39) 17 (11–24) 0.22
Candida, n (%) 1 (5) 1 (8) 0.75
n= 33 as the data restricted to patients who had at least two subsequent
endoscopies after baseline exam.
a≥ 15eos/hpf on histology.
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eosinophil counts also correlated with a drop in steroid dose.
On Kaplan–Meier analysis, half the patients had loss of
response to topical corticosteroid therapy by 18.5 months
and 75% of the sample has loss of treatment response by
29.6 months (Figure 3).
DISCUSSION
Topical corticosteroids are the first-line pharmacologic treat-
ment for EoE, and after an initial treatment course, they are
frequently used for maintenance therapy.17 However, our
knowledge of the best long-term management of patients with
initial response to steroid therapy is hobbled by a relative
paucity of the long-term follow-up data on this approach. In this
study of adult EoE patients who initially had a histologic
response and subsequent maintenance of topical cortico-
steroid therapy with fluticasone or budesonide, 61% had
histologic loss of response to treatment over a median follow-
up time of 11.7 months, with associated worsening of
endoscopic findings. There were no significant baseline
differences in eosinophil count, endoscopic severity score
(ESS), and steroid dose or type that predicted this loss of
treatment response. However, there was an association with
steroid dose at the time of histologic recurrence. Patients who
weremaintained on a high (daily41000 mcg of budesonide or
4880 mcg of fluticasone) steroid dose had lower odds of loss
of response compared to those who had a decrease in steroid
dose (daily ≤1000 budesonide or ≤ 880 mcg of fluticasone)
after achieving initial histologic response. This finding is
notable as it challenges the hypothesis that once histologic
remission is achieved with topical steroids, the medications
can be continued long-term without a detriment in efficacy.
Additionally, our finding that recurrence appears to be dose
dependent, and that re-increasing the dose may not lead to
histologic improvement is also an important observation,
potentially challenging whether decreasing the dose is
appropriate clinically.
These data augment a sparse literature on the long-term
outcomes of maintenance topical corticosteroid therapy in
EoE, particularly in adults. In one prospective cohort of
pediatric EoE patients,18 swallowed fluticasone was shown to
be effective in maintaining symptom, endoscopic, and
histologic features over a follow-up period of 2 years. However,
in this study, patients were maintained on the same dose of
fluticasone during the entire follow-up period and thus may
have had more successful ongoing treatment response. Even
in this study, with its standardized high dose of steroids, by two
years of follow-up eosinophil counts were noted to increase
Table 3 Endoscopic findings, eosinophil count, and mean steroid dose at follow-up time periodsa from baseline endoscopy
Baseline 0–6 months 6–12 months 12–24 months 424 months
Endoscopies, n (%) 55 (30) 30 (16) 24 (13) 37 (20) 38 (21)
Maximum eos/hpf, mean± s.d. 66±62 2±4 18± 29 27±42 40±59
Endoscopic findings, n (%)
Edema 14 (26) 4 (9) 2 (8) 7 (19) 14 (37)
Rings 44 (81) 27 (57) 15 (63) 25 (68) 27 (71)
Exudates 23 (43) 2 (4) 2 (8) 7 (24) 17 (45)
Furrows 38 (70) 8 (17) 6 (25) 17 (46) 19 (50)
Strictures 20 (36) 9 (19) 8 (33) 12 (32) 15 (39)
Endoscopic severity score (ESS)b, mean± s.d. 2.6± 1.4 1.1±1 1.4± 0.9 1.9±1.3 2.4±1.5
Mean steroid dose, mcg, mean± s.d.
Budesonide 0±0 2250±920 1833±794 1344±1172 1941±1130
Fluticasone 0±0 1540±407 1467±454 1100±660 825±367
PPI, n (%)
Highc 36 (68) 9 (19) 4 (17) 2 (5) 4 (11)
Lowd 7 (13) 26 (55) 11 (48) 11 (30) 11 (29)
None 10 (19) 12 (26) 8 (35) 24 (65) 23 (61)
aThe data from per-endoscopy analysis so each patient may be represented more than once during a specific follow-up interval. bEach EREFS finding (edema, rings,
exudates, furrows and strictures) scored as absent or present (score range: 0–5). cPPI dosed twice a daydPPI dosed daily.
Figure 1 Mean maximum eosinophil count and Endoscopic Severity Scores
(ESS) at baseline and follow-up time periods in adult EoE patients treated with topical
steroid treatment. Each EREFS finding (edema, rings, exudates, furrows and
strictures) scored as absent or present for ESS score (range: 0–5). The data is from
per-endoscopy analysis so each patient may be represented more than once during a
specific follow-up interval.
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above the level seen after the initial response. This deteriora-
tion of histological effect is consistent with our data. A similar
trend was noted in a separate retrospective pediatric cohort
study.19 In a randomized multicenter trial9 of patients of all
ages, daily treatment with 1760 mcg of swallowed fluticasone
resulted in histologic remission in 65–77% of the patients after
3 months. Of the 15 patients that had initial histologic
response, the dose of fluticasone was reduced to 880 mcg
after 3 months. Interestingly, a large proportion of this
maintenance group (27%) lost response in the subsequent
3 months. The only RCT in adults to assess maintenance
treatment in patients who initially responded to swallowed
budesonide randomized the patients to amaintenance dose of
0.5 mg daily or to placebo for a year.5 In the treatment
arm (n= 14), the eosinophil load increased from 0.4 to
31.8 eos/hpf, and only 36% maintained a remission of 5 eos/
hpf, indicating that this dose was likely too low for long-term
use. However, doses of budesonide in our study were higher
than this, and we still had a similar rate of loss of histologic
response.
Perhaps the most comparable study is a recent open-label
extension of a double-blind randomized controlled trial of
budesonide oral suspension.28 In this study, of adolescents
and adults initially treated with the medication at 2 mg twice
daily, 47% of the initial histologic responders were able to
maintain response, and non-response was most frequent in
those patients who decreased to 2 mg once daily dosing. This
is consistent with our finding that the loss of response in EoE
patients who initially responded to topical corticosteroids
correlated with dose reduction, especially for budesonide.
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Figure 2 Mean maximum eosinophil count (eos/hpf) and endoscopic severity scores (ESS) at baseline and follow-up time periods by steroid type and use of high dose of
proton-pump inhibitor (PPI). Each EREFS finding (edema, rings, exudates, furrows and strictures) scored as absent or present for ESS score (range: 0–5). The data is from
per-endoscopy analysis so each patient may be represented more than once during a specific follow-up interval. High-dose PPI defined as twice a day dosing.
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In our practice, the general approach is to use the lowest
topical steroid dose for maintenance that continues to achieve
histologic and clinical remission, and we typically reduce the
steroid dose by half in patients who show initial histologic
response. The results of this study suggest that a dose
reduction in steroid responding EoE patients may result in a
higher risk of disease relapse, and patients do not always
re-achieve remission. The data also raise the question of
whether “steroid resistance” may develop over time, which is
seen in other conditions such as inflammatory bowel disease
(IBD).29 However, more investigation would be needed to
determine if this phenomenon of steroid resistance exists in
EoE, and if it does, what the mechanism would be.
Our study is limited by the retrospective design, and the
study population is from a single-center tertiary care referral
center, which can limit generalizability. Because patients were
treated and followed per clinical protocol, we may have
preferentially included patients who were not doing well and
returned for ongoing care and subsequent endoscopies. If
patients maintained remission and were doing well clinically,
they might not be seen frequently and this could give the
impression that long-term outcomes are worse than they
actually are. This might in turn inflate the apparent proportion
of patients becoming non-responsive to steroids. However,
even if all 22 of the patients satisfying inclusion criteria for the
study but not seen in follow-up had no treatment failure, the
overall loss of response rate would still be an unacceptably
high 36% (20 out of 55). Also, if high–dose steroids are more
effective than low dose steroids in maintaining treatment
response, onewould expect differential loss of follow-up due to
effective therapy to attenuate, and not accentuate our primary
finding. This is because high-dose patients who were doing
poorly would be preferentially included in the study. However,
issues regarding differential dropout can only be definitively
addressed with a prospective study with per-protocol follow-up
endoscopies at regular intervals. While the small sample size
is also a limitation, this is a result of our stringent inclusion
criteria. We purposefully restricted the sample size to only
those who had an initial response, were maintained on steroid
treatment for 75–100% of the follow-up time, and had
complete data on steroid dosing, and endoscopic and
histologic findings. Our sample size is also comparable to
other studies in adult EoE patients focusing on long-term
steroid treatment outcomes.18,28 Another limitation is that the
symptom datawere not collected in an objectivemanner with a
validated symptom score, so we cannot comment on sympto-
matic relapse and whether symptoms correlated with histolo-
gic loss of response. Finally, patient adherence could not be
fully measured due to the retrospective study design. Despite
these limitations, our study adds to the existing literature and
shows that rates of loss of response to steroid therapy are
similar to findings in the pediatric population.18 In addition, we
showed that a decrease in steroid dose results in higher risk of
loss of response, and questions the current practice in many
centers of routinely lowering steroid dose for maintenance
therapy. If such a strategy results in high rates of possible
steroid resistance, which cannot be overcome by subse-
quently increasing the steroid dose, perhaps maintenance at
the same dose as initial induction therapy is a superior
strategy. These issues will need to be carefully studied, with
the symptom data collected with validated instruments, in a
prospective setting in the future.
In conclusion, in this retrospective cohort study of adult EoE
patients who were initial histologic responders to topical
corticosteroid therapy, half had loss of histologic response by
18 months from baseline exam, with associated worsening in
endoscopic findings. Maintenance of histologic response
appeared to be longer with fluticasone compared to budeso-
nide and loss of response was associated with a dose
reduction of daily ≤ 1000 budesonide or ≤880 mcg of
fluticasone. In adult EoE patients, while guidelines recom-
mend first-line treatment with swallowed topical corticoster-
oids, there is little guidance regarding the duration and
management of dose changes. Results of this study suggest
that maintaining the initial dose of topical budesonide or
fluticasone may result in persistent maintenance of histologic
and endoscopic remission, and that the practice of dose
reduction, which is primarily done in an attempt to minimize
steroid exposure and side effects, may not be the optimal
strategy for best long-term outcomes.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Topical corticosteroids such as budesonide or fluticasone
are the recommend first-line pharmacologic treatment for
treatment of eosinophilic esophagitis (EoE).
✓ After initial treatment response following a course of steroid
treatment, there is controversy on whether EoE patients
need to be indefinitely continued on steroid therapy for
maintenance of disease remission.
WHAT IS NEW HERE
✓ In this study of adult EoE patients who were histologic
responders to either fluticasone or budesonide, 61% had
loss of treatment by 12 months.
✓ Histologic recurrence was associated with a decrease in
steroid dose after initial response.
✓ Results from this study suggest that maintaining the initial
dose of topical fluticasone or budesonide may result in
sustained endoscopic and histologic remission.
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